clenbuterol has been researched along with Amyotrophic Lateral Sclerosis in 3 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clenbuterol, a beta-agonist, has plausible mechanisms for treating amyotrophic lateral sclerosis (ALS)." | 8.31 | Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. ( Bedlack, R; Koeberl, DD; Li, X; Lutz, MW, 2023) |
| "Clenbuterol, a beta-agonist, has plausible mechanisms for treating amyotrophic lateral sclerosis (ALS)." | 4.31 | Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis. ( Bedlack, R; Koeberl, DD; Li, X; Lutz, MW, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Koeberl, DD | 1 |
| Lutz, MW | 1 |
| Bedlack, R | 1 |
| Sorarù, G | 1 |
| Pegoraro, E | 1 |
| Spinella, P | 1 |
| Turra, S | 1 |
| D'Ascenzo, C | 1 |
| Baggio, L | 1 |
| Mantovan, MC | 1 |
| Vergani, L | 1 |
| Angelini, C | 1 |
| Brooks, BR | 1 |
| Juhasz-Poscine, K | 1 |
| Waclawik, A | 1 |
| Sanjak, M | 1 |
| Belden, D | 1 |
| Roelke, K | 1 |
| Parnell, J | 1 |
| Weasler, C | 1 |
1 review available for clenbuterol and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: beta-2 adrenergic agonists.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Amyotrophic Lateral Sclerosis; Clenbu | 2000 |
1 trial available for clenbuterol and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
A pilot trial with clenbuterol in amyotrophic lateral sclerosis.
Topics: Adrenergic beta-Agonists; Adult; Aged; Amyotrophic Lateral Sclerosis; Clenbuterol; Female; Humans; M | 2006 |
1 other study available for clenbuterol and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Clenbuterol Treatment Is Safe and Associated With Slowed Disease Progression in a Small Open-Label Trial in Patients With Amyotrophic Lateral Sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Clenbuterol; Disease Progression; Female; Hand Strength; Humans; Male | 2023 |